Daily weight loss pill helps patients lose 12% of body weight BBCEli Lilly shares drop after obesity pill shows modest late-stage trial results CNBCLilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity | Eli Lilly and Company Eli Lilly and Company
https://news.google.com/rss/articles/CBMiXEFVX3lxTE9ZVVBYVXpYSnFkYlhjQlVQVk45elFnX25Qb3p0azhiWG03V3FLZFdlQkYzeXN3WlZtdHVkdi1vb0huM0R3Zk9wM0NUWFpVb3Q3cUVfRXQ1OHlRR3JS0gFiQVVfeXFMTWdfVjU2ZGllc1RkNmYtUWhVX2c0NjZRbFZEUzg5dVo4V0NJMkFsRXhGQ09DeDhCdXQzbldjUWFYbHl5VVVUa1ZJRmQwWXQ3a1EyUkpZTEZGdWFDWEdtYzNmaEE?oc=5
Daily weight loss pill helps patients lose 12% of body weight – BBC
